Moving together: Is there a global convergence in drug evaluation? (Part 2)

Being too strict can have an impact on the country's industry, as well as limiting choice for physicians and patients. "In Australia and New Zealand in the early 90s, the regulatory bodies were so hard on the industry, blacklisting drugs, that the bulk of the companies left and set up elsewhere," says Tania MacLeod, President, Market Access Solutions, Canada, which provides strategic market access consultancy.